opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
Drug company decided to terminate all sponsored clinical studies involving rilotumumab.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Drug company withdrawal of support for investigational agent in this indication.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Drug development suspended	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on RetaspimycinÊ HCL	[ "Success", "Endpoint_Met" ]	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	true
Drug related AEs observed upon repeat dosing that with longer treatment duration could becomeÊ worse. Required action on some biomarkers not observed.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Drug supply issue - Contracts with New source Genzyme Canada are in negotiation	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug supply shortage. Study should reopen in February, 2008"	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug supply unavailable.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug unavailable	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug was not sent	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug was pulled from the market.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Drug withdrawal	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drug withdrawn from market	[ "Business_Administrative", "Study_Design" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Drugs unavailable- study terminated 1/2/18	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Drugs unavailable:unable to make radioactive topotecan	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to COVID -19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID -19, study is suspended to accrual only	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID-19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID-19 and tissue resource not available at this time	[ "Covid19", "Logistics_Resources" ]	false	false	true	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to COVID-19 outbreak, study is temporarily suspended.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID-19 policies.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID-19, effective 3/19/2020 recruitment is halted until further notice	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to COVID-19.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to FDA comments, indications for use were chnaged and a different population will be proposed shortly"	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporaryÊ suspension	[ "Study_Design", "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	true	false	false
Due to MOH request.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to PI's Study_Design with IRB requirements	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to Sponsor's decision, only 12 patients were randomized & completed study.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to Sponsor's financial reasons	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to a lack of IP supply and then terminated because they were combined into one new study with the new IP formulation.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to a low recruitment rate since start of recruitment period.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to a single, unexpected serious event, the trial was stopped.	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to a substantial response to placebo an interim analysis indicated the need for a larger than expected study population to achieve the level of significance	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to administrative reasons	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to administrative reasons not related to efficacy or safety.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to an administrative reason	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to business considerations; not due to toxicities or adverse events.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to business decisions	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to celecoxib safety issues	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to changes in portofolio review	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to clinical trial supplies shortage	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to company decision to focus resources on a larger, controlled study in this patient population."	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to company decision to focus resources on the finalisation of three ongoing studies in the region	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to concerns about potential liver safety (See Detailed Description)	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to continuing review	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to country-level restrictions regarding COVID19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to decrease in Avaulta mesh kit usage & inability to recruit study subjects.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to difficult enrollment, and investigator agreed to terminate this study."	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to difficult patient enrollment.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to difficulty in patient recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to difficulty with enrollment of subjects	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to dose re-selection	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to drug unavailability	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to efficacy results of interim analysis	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to emerging safety data	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to enrollment challenges resulting from changing treatment patterns in the use ofÊ cetuximab, the study has been terminated. No patients remain on study.	[ "Study_Design", "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
Due to ethical concerns regard to the results from the WHI study	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to existing evidence eligible patients receive CRT treatment in first place	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to extreme toxicity	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to failure to control sufficient patients in the active arm, this study has now been closed."	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to financial issues of Restora spacer company.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to funding issues.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to graft failure.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to high incidence of neurological complication in those with ilioinguinal block	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to inadequate recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to insufficient funds	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to insufficient patient inclusion the study has been stopped prematurely.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to internal reasons study was not performed.	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Due to lack of availability of study participants to accommodate the study design	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to lack of coordinator coverage	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to lack of efficacy	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to lack of funding	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to lack of funding and a primary co-investigator of the trial leaving the institution.	[ "Business_Administrative", "Logistics_Resources", "Study_Staff_Moved" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	true	false
Due to lack of malaria patients in Zanzibar the study has been suspended.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to lack of recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to lack of recruitment and loss of the French principal investigator.	[ "Insufficient_Enrollment", "Study_Staff_Moved" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	true	false
Due to lack of sufficient efficacy.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to lack of supply of the investigational product.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to late study start, the possibility to enroll enough subjects dropped below the limit toÊ provide scientifically acceptable data, hence study was cancelled.	[ "Insufficient_Enrollment", "Insufficient_Data", "Study_Design" ]	false	false	false	false	false	true	true	false	false	false	false	false	false	false	true	false	false
Due to limited pool of eligble WNV patients	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to low accrual	[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
Due to no patient enrollment this study was withdrawn/closed	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to non-feasibility	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to numerous delays in study start-up process...	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to other projects priority	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to poor accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor accrual of the study	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor compliance with study drug administration.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to poor enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor enrollment rate	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor enrollment, this study was terminated."	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor patient enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to poor patient recruitment, a decision was made to terminate this trial."	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to portfolio and logistical issues, this study will not be re-started at the present time. The study is not being terminated for safety reasons."	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to portfolio/business decisions by the sponsor	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to potential concerns about liver safety (See Detailed Description)	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to projected low enrollment, UroGen has decided not to move forward with the study.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false

Drug company decided to terminate all sponsored clinical studies involving rilotumumab.

[ "Business_Administrative" ]

false

true

false

Drug company withdrawal of support for investigational agent in this indication.

[ "Business_Administrative" ]

false

true

false

Drug development suspended

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on RetaspimycinÊ HCL

[ "Success", "Endpoint_Met" ]

false

true

false

true

Drug related AEs observed upon repeat dosing that with longer treatment duration could becomeÊ worse. Required action on some biomarkers not observed.

[ "Negative" ]

false

true

false

Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.

[ "Business_Administrative" ]

false

true

false

Drug supply issue - Contracts with New source Genzyme Canada are in negotiation

[ "Logistics_Resources" ]

false

true

false

Drug supply shortage. Study should reopen in February, 2008"

[ "Logistics_Resources" ]

false

true

false

Drug supply unavailable.

[ "Logistics_Resources" ]

false

true

false

Drug unavailable

[ "Logistics_Resources" ]

false

true

false

Drug was not sent

[ "Logistics_Resources" ]

false

true

false

Drug was pulled from the market.

[ "Study_Design" ]

false

true

false

Drug withdrawal

[ "Logistics_Resources" ]

false

true

false

Drug withdrawn from market

[ "Business_Administrative", "Study_Design" ]

false

true

false

true

false

Drugs unavailable- study terminated 1/2/18

[ "Logistics_Resources" ]

false

true

false

Drugs unavailable:unable to make radioactive topotecan

[ "Logistics_Resources" ]

false

true

false

Due to COVID -19

[ "Covid19" ]

false

true

false

Due to COVID -19, study is suspended to accrual only

[ "Covid19" ]

false

true

false

Due to COVID-19

[ "Covid19" ]

false

true

false

Due to COVID-19 and tissue resource not available at this time

[ "Covid19", "Logistics_Resources" ]

false

true

false

true

false

Due to COVID-19 outbreak, study is temporarily suspended.

[ "Covid19" ]

false

true

false

Due to COVID-19 policies.

[ "Covid19" ]

false

true

false

Due to COVID-19, effective 3/19/2020 recruitment is halted until further notice

[ "Covid19" ]

false

true

false

Due to COVID-19.

[ "Covid19" ]

false

true

false

Due to FDA comments, indications for use were chnaged and a different population will be proposed shortly"

[ "Study_Design" ]

false

true

false

Due to Health Canada losartan recall, a new formulation being added to the protocol/ temporaryÊ suspension

[ "Study_Design", "Safety_Sideeffects" ]

false

true

false

Due to MOH request.

[ "Regulatory" ]

false

true

false

Due to PI's Study_Design with IRB requirements

[ "Study_Design" ]

false

true

false

Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point

[ "Negative" ]

false

true

false

Due to Sponsor's decision, only 12 patients were randomized & completed study.

[ "Insufficient_Enrollment" ]

false

true

false

Due to Sponsor's financial reasons

[ "Business_Administrative" ]

false

true

false

Due to a lack of IP supply and then terminated because they were combined into one new study with the new IP formulation.

[ "Insufficient_Enrollment" ]

false

true

false

Due to a low recruitment rate since start of recruitment period.

[ "Insufficient_Enrollment" ]

false

true

false

Due to a single, unexpected serious event, the trial was stopped.

[ "Safety_Sideeffects" ]

false

true

false

Due to a substantial response to placebo an interim analysis indicated the need for a larger than expected study population to achieve the level of significance

[ "Negative" ]

false

true

false

Due to administrative reasons

[ "Business_Administrative" ]

false

true

false

Due to administrative reasons not related to efficacy or safety.

[ "Business_Administrative" ]

false

true

false

Due to an administrative reason

[ "Business_Administrative" ]

false

true

false

Due to business considerations; not due to toxicities or adverse events.

[ "Business_Administrative" ]

false

true

false

Due to business decisions

[ "Business_Administrative" ]

false

true

false

Due to celecoxib safety issues

[ "Safety_Sideeffects" ]

false

true

false

Due to changes in portofolio review

[ "Business_Administrative" ]

false

true

false

Due to clinical trial supplies shortage

[ "Logistics_Resources" ]

false

true

false

Due to company decision to focus resources on a larger, controlled study in this patient population."

[ "Another_Study" ]

true

false

Due to company decision to focus resources on the finalisation of three ongoing studies in the region

[ "Another_Study" ]

true

false

Due to concerns about potential liver safety (See Detailed Description)

[ "Safety_Sideeffects" ]

false

true

false

Due to continuing review

[ "Regulatory" ]

false

true

false

Due to country-level restrictions regarding COVID19

[ "Covid19" ]

false

true

false

Due to decrease in Avaulta mesh kit usage & inability to recruit study subjects.

[ "Insufficient_Enrollment" ]

false

true

false

Due to difficult enrollment, and investigator agreed to terminate this study."

[ "Insufficient_Enrollment" ]

false

true

false

Due to difficult patient enrollment.

[ "Insufficient_Enrollment" ]

false

true

false

Due to difficulty in patient recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Due to difficulty with enrollment of subjects

[ "Insufficient_Enrollment" ]

false

true

false

Due to dose re-selection

[ "Study_Design" ]

false

true

false

Due to drug unavailability

[ "Logistics_Resources" ]

false

true

false

Due to efficacy results of interim analysis

[ "Negative" ]

false

true

false

Due to emerging safety data

[ "Safety_Sideeffects" ]

false

true

false

Due to enrollment challenges resulting from changing treatment patterns in the use ofÊ cetuximab, the study has been terminated. No patients remain on study.

[ "Study_Design", "Insufficient_Enrollment" ]

false

true

false

true

false

Due to ethical concerns regard to the results from the WHI study

[ "Another_Study" ]

true

false

Due to existing evidence eligible patients receive CRT treatment in first place

[ "Another_Study" ]

true

false

Due to extreme toxicity

[ "Safety_Sideeffects" ]

false

true

false

Due to failure to control sufficient patients in the active arm, this study has now been closed."

[ "Insufficient_Enrollment" ]

false

true

false

Due to financial issues of Restora spacer company.

[ "Logistics_Resources" ]

false

true

false

Due to funding issues.

[ "Insufficient_Enrollment" ]

false

true

false

Due to graft failure.

[ "Study_Design" ]

false

true

false

Due to high incidence of neurological complication in those with ilioinguinal block

[ "Safety_Sideeffects" ]

false

true

false

Due to inadequate recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Due to insufficient funds

[ "Business_Administrative" ]

false

true

false

Due to insufficient patient inclusion the study has been stopped prematurely.

[ "Insufficient_Enrollment" ]

false

true

false

Due to internal reasons study was not performed.

[ "Invalid_Reason" ]

false

true

false

Due to lack of availability of study participants to accommodate the study design

[ "Insufficient_Enrollment" ]

false

true

false

Due to lack of coordinator coverage

[ "Logistics_Resources" ]

false

true

false

Due to lack of efficacy

[ "Negative" ]

false

true

false

Due to lack of funding

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

Due to lack of funding and a primary co-investigator of the trial leaving the institution.

[ "Business_Administrative", "Logistics_Resources", "Study_Staff_Moved" ]

false

true

false

true

false

true

false

Due to lack of malaria patients in Zanzibar the study has been suspended.

[ "Insufficient_Enrollment" ]

false

true

false

Due to lack of recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Due to lack of recruitment and loss of the French principal investigator.

[ "Insufficient_Enrollment", "Study_Staff_Moved" ]

false

true

false

true

false

Due to lack of sufficient efficacy.

[ "Negative" ]

false

true

false

Due to lack of supply of the investigational product.

[ "Logistics_Resources" ]

false

true

false

Due to late study start, the possibility to enroll enough subjects dropped below the limit toÊ provide scientifically acceptable data, hence study was cancelled.

[ "Insufficient_Enrollment", "Insufficient_Data", "Study_Design" ]

false

true

false

true

false

Due to limited pool of eligble WNV patients

[ "Insufficient_Enrollment" ]

false

true

false

Due to low accrual

[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

true

false

Due to no patient enrollment this study was withdrawn/closed

[ "Insufficient_Enrollment" ]

false

true

false

Due to non-feasibility

[ "Logistics_Resources" ]

false

true

false

Due to numerous delays in study start-up process...

[ "Logistics_Resources" ]

false

true

false

Due to other projects priority

[ "Business_Administrative" ]

false

true

false

Due to poor accrual

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor accrual of the study

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor compliance with study drug administration.

[ "Study_Design" ]

false

true

false

Due to poor enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor enrollment rate

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor enrollment, this study was terminated."

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor patient enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Due to poor patient recruitment, a decision was made to terminate this trial."

[ "Insufficient_Enrollment" ]

false

true

false

Due to portfolio and logistical issues, this study will not be re-started at the present time. The study is not being terminated for safety reasons."

[ "Business_Administrative" ]

false

true

false

Due to portfolio/business decisions by the sponsor

[ "Business_Administrative" ]

false

true

false

Due to potential concerns about liver safety (See Detailed Description)

[ "Safety_Sideeffects" ]

false

true

false

Due to projected low enrollment, UroGen has decided not to move forward with the study.

[ "Insufficient_Enrollment" ]

false

true

false

Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis

[ "Another_Study" ]

true

false